Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer

World Journal of Urology

Volumn 32, Issue 6, 2014, Pages 1477-1484

  Wang, Jianwen ^a   Zhang, Xiaodong ^a   Wei, Ping ^a   Zhang, Junhui ^a   Niu, Yinong ^a   Kang, Ning ^a   Zhang, Yuxiang ^b   Zhang, Weili ^c   Xing, Nianzeng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Bladder cancer; Caspase 3; Livin; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; BIRC7 PROTEIN, HUMAN; CASPASE 3; INHIBITOR OF APOPTOSIS PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

AGED; CARCINOMA; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL; URINARY BLADDER NEOPLASMS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; CARCINOMA; CASPASE 3; FEMALE; FOLLOW-UP STUDIES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84912054669     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1246-0     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62:10–29
2. Parkin MD, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
3. Shariat SF, Casella R, Khoddami SM et al (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171:626–630
4. Ashhab Y, Alian A, Polliack A et al (2001) Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 495:56–60
5. Karam JA, Lotan Y, Ashfaq R et al (2007) Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 70:482–486
6. Alnemri ES, Livingston DJ, Nicholson DW et al (1996) Human ICE/CED-3 protease nomenclature. Cell 87:171–172
7. Dai CH, Li J, Shi SB et al (2010) Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol 40:327–335
8. Gazzaniga P, Gradilone A, Giuliani L et al (2003) Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14:85–90
9. Smolewski P, Robak T (2011) Inhibitors of apoptosis protein (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr Mol Med 11:633–649
10. Chen N, Gong J, Chen X et al (2009) Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinic pathologic significance. Hum Pathol 40:950–956
11. Sobin LH, Wittekind C (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York, pp 199–202
12. Ebele JN, Sauter G, Epstein JI et al (2004) World Health Organization classification of tumors: pathology and genetics of tumors of the urinary system and male genital organs. IARC Press, Lyon, pp 90–91
13. Yin W, Chen N, Zhang Y et al (2006) Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol 19:1487–1497
14. Atlasi Y, Mowla SJ, Ziaee SA (2009) Differential expression of survivin and its splice variants, survivin-DEx3 and survivin-2B, in bladder cancer. Cancer Detect Prev 32:308–313
15. Weikert S, Christoph F, Schrader M et al (2005) Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116:100–104
16. Schultz I, Kiemeney L, Witjes JA et al (2003) Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 23:3327–3331
17. Birkhahn M, Mitra AP, Williams AJ et al (2010) Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 57:12–20
18. Chen DJ, Huerta S (2009) Smac mimetics as new cancer therapeutics. Anticancer Drugs 20:646–658
19. Yang D, Song X, Zhang J et al (2010) Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. Acta Biochim Biophys Sin 42:137–144
20. Liu HB, Kong CZ, Zeng Y et al (2009) Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment. Urol Oncol 27:271–283
21. Xi RC, Sheng YR, Chen WH et al (2013) Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol 107:550–554
22. Caldas H, Honsey LE, Altura RA (2005) Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 4:11–15
23. Ceballos-Cancino G, Espinosa M, Maldonado V et al (2007) Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene 26:7969–7975
24. Giodini A, Kallio MJ, Wall NR et al (2002) Regulation of micro- tubule stability and mitotic progression by survivin. Cancer Res 62:2462–2467
25. Tu SP, Jiang XH, Lin MC et al (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63:7724–7732
26. Margulis V, Lotan Y, Shariat SF (2008) Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 26:59–65
27. Wang H, Xi X, Kong X et al (2004) The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 130:487–490
28. Salvesen GS (2002) Caspases: opening the boxes and interpreting the arrow. Cell Death Differ 9:3–5
29. Liu C, Wu X, Luo C et al (2010) Antisense oligonucleotide targeting Livin induces apoptosis of human bladder cancer cell via a mechanism involving caspase 3. J Exp Clin Cancer Res 29:63–68
30. Karam JA, Lotan Y, Karakiewicz PI et al (2007) Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8:128–136